Matthew Mei, MD

City of Hope National Medical Center

Poster(s):

• 1404 - A Phase 2 study with Tafasitamab and Zanubrutinib in newly diagnosed chronic lymphocytic leukemia/small lymphocytic lymphoma – TaZa CLL Study

• 1904 - Development and implementation of a novel flow cytometry CD19-agnostic MRD assay in CLL, including in patients treated with anti-CD19 antibody tafasitamab